1223404-89-4

Usage

Uses

Used in Pharmaceutical Industry:
(2R)-2-(2,5-difluorophenyl)-1-pyrazolo[1,5-a]pyrimidin-5-ylpyrrolidine is used as a lead compound for drug development due to its potential antitumor, antiviral, and anti-inflammatory properties. The presence of the pyrazolo[1,5-a]pyrimidin-5-yl group suggests that (2R)-2-(2,5-difluorophenyl)-1-{pyrazolo[1,5-a]pyrimidin-5-yl}pyrrolidine may exhibit therapeutic effects similar to other pyrazolo[1,5-a]pyrimidine derivatives that have been studied for their ability to modulate biological processes and treat various diseases.
Used in Chemical Research:
In the field of chemical research, (2R)-2-(2,5-difluorophenyl)-1-pyrazolo[1,5-a]pyrimidin-5-ylpyrrolidine serves as a model compound for studying the effects of molecular structure on biological activity. The unique combination of functional groups in this molecule allows researchers to investigate the role of specific structural elements in mediating interactions with biological targets and understanding the underlying mechanisms of action.
Used in Drug Design:
(2R)-2-(2,5-difluorophenyl)-1-pyrazolo[1,5-a]pyrimidin-5-ylpyrrolidine is utilized as a template in drug design for the development of novel therapeutic agents. Its complex molecular structure provides a foundation for the rational design of new compounds with improved pharmacological properties, such as enhanced potency, selectivity, and reduced side effects. By modifying specific functional groups or incorporating additional moieties, chemists can optimize the biological activity and pharmacokinetic profile of (2R)-2-(2,5-difluorophenyl)-1-{pyrazolo[1,5-a]pyrimidin-5-yl}pyrrolidine for various therapeutic applications.

Upstream product

• 1218935-59-1 (R)-(+)-2-(2,5-difluorophenyl)pyrrolidine 
• 29274-24-6 5-chloropyrazolo[1,5-a]pyrimidine 
• 1443538-31-5 (R)-1-((S)-tert-butylsulfinyl)-2-(2,5-difluorophenyl)pyrrolidine 
• 1218935-60-4 (2R)-2-(2,5-difluorophenyl)pyrrolidine hydrochloride 
• 1216260-42-2 4‐chloro‐1‐(2,5-difluorophenyl)butan-1-one 
• 29274-22-4 pyrazolo[1,5-a]pyrimidine-5-ol 

Downstream Products

• 1223404-90-7 (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-nitropyrazolo[1,5-a]pyrimidine 

Relevant academic research and scientific papers

Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation

Tropomyosin receptor kinase (TRK) inhibition is an effective therapeutic approach for treatment of a variety of cancers. Despite the use of first-generation TRK inhibitor (TRKI) larotrectinib (1) resulting in significant therapeutic response in patients, acquired resistance develops invariably. The emergence of secondary mutations occurring at the solvent-front, xDFG, and gatekeeper regions of TRK represents a common mechanism for acquired resistance. However, xDFG mutations remain insensitive to second-generation macrocyclic TRKIs selitrectinib (3) and repotrectinib (4) designed to overcome the resistance mediated by solvent-front and gatekeeper mutations. Here, we report the structure-based drug design and discovery of a next-generation TRKI. The structure-activity relationship studies culminated in the identification of a promising drug candidate 8 that showed excellent in vitro potency on a panel of TRK mutants, especially TRKAG667C in the xDFG motif, and improved in vivo efficacy than 1 and 3 in TRK wild-type and mutant fusion-driven tumor xenograft models, respectively.

FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS

The disclosure provides novel chemical compounds represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases. In some compounds of Formula I, Q is —CH═CR3C(O)NR4R5, —C≡CC(O)NR4R5, or

SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS

Compounds of Formula (I) in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor.